• 10 October 2011
  • News
  • By

Tech Solutions CSO

The business objective of any BioIT company is to support the pharma companies, which are under tremendous pressure due to rising R&D costs, drying of product pipeline and regulatory hurdles. Companies, such as Strand Life Sciences and CellWorks, have been working towards meeting this aim.

In this issue of CSO series, we focus on the contributions of Dr Kalyanasundaram Subramanian, CSO, Strand Life Sciences, and Dr Shireen Vali, CSO, CellWorks, towards development of technology-based solutions to enable drug discovery R&D, improve productivity and success rate of the process, reduce costs, increase efficiency, and identify potential side-effects.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email